endo-iwr 1 Search Results


iwr1e  (Tocris)
95
Tocris iwr1e
Iwr1e, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endo-iwr+1/endo-IWR+1/10__1002_slash_adfm__202512621-350-7-8
Average 95 stars, based on 1 article reviews
iwr1e - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
iwr 1  (MedChemExpress)
96
MedChemExpress iwr 1
( A ) qPCR from mouse EHBD organoids for the 4 most abundant WNT ligands of the EHBD. ( B ) Images from mouse organoid cultures 1, 2, and 3 passages after being grown in WNT-free media. ( C ) Bulk RNA-Seq analysis of human organoids for WNT ligands. ( D ) Timeline for C59 administration to inhibit WNT secretion by mouse organoids. ( E – G ) Mouse organoid images ( E ), size ( F ), and viability ( G ) measurements after treatment with 10 μM C59. ( H ) Timeline <t>for</t> <t>IWR-1</t> administration to inhibit β-catenin in mouse organoids. ( I – K ) Mouse organoid images ( I ), size ( J ), and viability ( K ) following 5 μM IWR-1 treatment. ( L ) Timeline for C59 administration in human organoids. ( M – O ) Human organoid images ( M ), size ( N ), viability ( O ) after 10 μM C59 treatment. ( P ) Timeline for IWR-1 treatment in human organoids. ( Q – S ) Human organoid images ( Q ), size ( R ), and viability ( S ) following 5 μM IWR-1 treatment. Size and viability measurements are normalized to the vehicle controls. Scale bar: 500 μm. One-sample t test. * P < 0.05, ** P < 0.01, *** P < 0.001, n = 3–5 biological replicates.
Iwr 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endo-iwr+1/IWR-1/pmc11790017-238-0-1
Average 96 stars, based on 1 article reviews
iwr 1 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
endo iwr1  (Tocris)
99
Tocris endo iwr1
( A ) qPCR from mouse EHBD organoids for the 4 most abundant WNT ligands of the EHBD. ( B ) Images from mouse organoid cultures 1, 2, and 3 passages after being grown in WNT-free media. ( C ) Bulk RNA-Seq analysis of human organoids for WNT ligands. ( D ) Timeline for C59 administration to inhibit WNT secretion by mouse organoids. ( E – G ) Mouse organoid images ( E ), size ( F ), and viability ( G ) measurements after treatment with 10 μM C59. ( H ) Timeline <t>for</t> <t>IWR-1</t> administration to inhibit β-catenin in mouse organoids. ( I – K ) Mouse organoid images ( I ), size ( J ), and viability ( K ) following 5 μM IWR-1 treatment. ( L ) Timeline for C59 administration in human organoids. ( M – O ) Human organoid images ( M ), size ( N ), viability ( O ) after 10 μM C59 treatment. ( P ) Timeline for IWR-1 treatment in human organoids. ( Q – S ) Human organoid images ( Q ), size ( R ), and viability ( S ) following 5 μM IWR-1 treatment. Size and viability measurements are normalized to the vehicle controls. Scale bar: 500 μm. One-sample t test. * P < 0.05, ** P < 0.01, *** P < 0.001, n = 3–5 biological replicates.
Endo Iwr1, supplied by Tocris, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endo-iwr+1/endo-IWR+1/pm25273086-202-28-29
Average 99 stars, based on 1 article reviews
endo iwr1 - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier
wnt inhibitor iwr1  (Biogems International)
93
Biogems International wnt inhibitor iwr1
( A ) qPCR from mouse EHBD organoids for the 4 most abundant WNT ligands of the EHBD. ( B ) Images from mouse organoid cultures 1, 2, and 3 passages after being grown in WNT-free media. ( C ) Bulk RNA-Seq analysis of human organoids for WNT ligands. ( D ) Timeline for C59 administration to inhibit WNT secretion by mouse organoids. ( E – G ) Mouse organoid images ( E ), size ( F ), and viability ( G ) measurements after treatment with 10 μM C59. ( H ) Timeline <t>for</t> <t>IWR-1</t> administration to inhibit β-catenin in mouse organoids. ( I – K ) Mouse organoid images ( I ), size ( J ), and viability ( K ) following 5 μM IWR-1 treatment. ( L ) Timeline for C59 administration in human organoids. ( M – O ) Human organoid images ( M ), size ( N ), viability ( O ) after 10 μM C59 treatment. ( P ) Timeline for IWR-1 treatment in human organoids. ( Q – S ) Human organoid images ( Q ), size ( R ), and viability ( S ) following 5 μM IWR-1 treatment. Size and viability measurements are normalized to the vehicle controls. Scale bar: 500 μm. One-sample t test. * P < 0.05, ** P < 0.01, *** P < 0.001, n = 3–5 biological replicates.
Wnt Inhibitor Iwr1, supplied by Biogems International, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endo-iwr+1/endo-IWR-1/pm36314397-467-20-23
Average 93 stars, based on 1 article reviews
wnt inhibitor iwr1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
endo iwr 1  (Tocris)
94
Tocris endo iwr 1
( A ) qPCR from mouse EHBD organoids for the 4 most abundant WNT ligands of the EHBD. ( B ) Images from mouse organoid cultures 1, 2, and 3 passages after being grown in WNT-free media. ( C ) Bulk RNA-Seq analysis of human organoids for WNT ligands. ( D ) Timeline for C59 administration to inhibit WNT secretion by mouse organoids. ( E – G ) Mouse organoid images ( E ), size ( F ), and viability ( G ) measurements after treatment with 10 μM C59. ( H ) Timeline <t>for</t> <t>IWR-1</t> administration to inhibit β-catenin in mouse organoids. ( I – K ) Mouse organoid images ( I ), size ( J ), and viability ( K ) following 5 μM IWR-1 treatment. ( L ) Timeline for C59 administration in human organoids. ( M – O ) Human organoid images ( M ), size ( N ), viability ( O ) after 10 μM C59 treatment. ( P ) Timeline for IWR-1 treatment in human organoids. ( Q – S ) Human organoid images ( Q ), size ( R ), and viability ( S ) following 5 μM IWR-1 treatment. Size and viability measurements are normalized to the vehicle controls. Scale bar: 500 μm. One-sample t test. * P < 0.05, ** P < 0.01, *** P < 0.001, n = 3–5 biological replicates.
Endo Iwr 1, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endo-iwr+1/endo-IWR+1/pmc12922212-101-41-42
Average 94 stars, based on 1 article reviews
endo iwr 1 - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
endo-iwr 1  (Biosynth Carbosynth)
N/A
Stabilises axin protein of Wnt signalling pathway. Stabilises axin protein of Wnt signalling pathway.
   Buy from Supplier

Image Search Results


( A ) qPCR from mouse EHBD organoids for the 4 most abundant WNT ligands of the EHBD. ( B ) Images from mouse organoid cultures 1, 2, and 3 passages after being grown in WNT-free media. ( C ) Bulk RNA-Seq analysis of human organoids for WNT ligands. ( D ) Timeline for C59 administration to inhibit WNT secretion by mouse organoids. ( E – G ) Mouse organoid images ( E ), size ( F ), and viability ( G ) measurements after treatment with 10 μM C59. ( H ) Timeline for IWR-1 administration to inhibit β-catenin in mouse organoids. ( I – K ) Mouse organoid images ( I ), size ( J ), and viability ( K ) following 5 μM IWR-1 treatment. ( L ) Timeline for C59 administration in human organoids. ( M – O ) Human organoid images ( M ), size ( N ), viability ( O ) after 10 μM C59 treatment. ( P ) Timeline for IWR-1 treatment in human organoids. ( Q – S ) Human organoid images ( Q ), size ( R ), and viability ( S ) following 5 μM IWR-1 treatment. Size and viability measurements are normalized to the vehicle controls. Scale bar: 500 μm. One-sample t test. * P < 0.05, ** P < 0.01, *** P < 0.001, n = 3–5 biological replicates.

Journal: JCI Insight

Article Title: WNT signaling contributes to the extrahepatic bile duct proliferative response to obstruction in mice

doi: 10.1172/jci.insight.181857

Figure Lengend Snippet: ( A ) qPCR from mouse EHBD organoids for the 4 most abundant WNT ligands of the EHBD. ( B ) Images from mouse organoid cultures 1, 2, and 3 passages after being grown in WNT-free media. ( C ) Bulk RNA-Seq analysis of human organoids for WNT ligands. ( D ) Timeline for C59 administration to inhibit WNT secretion by mouse organoids. ( E – G ) Mouse organoid images ( E ), size ( F ), and viability ( G ) measurements after treatment with 10 μM C59. ( H ) Timeline for IWR-1 administration to inhibit β-catenin in mouse organoids. ( I – K ) Mouse organoid images ( I ), size ( J ), and viability ( K ) following 5 μM IWR-1 treatment. ( L ) Timeline for C59 administration in human organoids. ( M – O ) Human organoid images ( M ), size ( N ), viability ( O ) after 10 μM C59 treatment. ( P ) Timeline for IWR-1 treatment in human organoids. ( Q – S ) Human organoid images ( Q ), size ( R ), and viability ( S ) following 5 μM IWR-1 treatment. Size and viability measurements are normalized to the vehicle controls. Scale bar: 500 μm. One-sample t test. * P < 0.05, ** P < 0.01, *** P < 0.001, n = 3–5 biological replicates.

Article Snippet: IWR-1 (MCE, HY-12238) stock solution was made by reconstituting IWR-1 at a concentration of 10 mM in DMSO and storing it at –80°C.

Techniques: RNA Sequencing